Sagent Pharmaceuticals,
Inc. SGNT, a leader of specialty pharmaceutical products with an
emphasis on the injectable market, today announced the launch of Flumazenil
Injection, USP, a benzodiazepine antagonist, in two latex-free vial
presentations. According to IMS for the 12 months ending September 2012, the
US market for Flumazenil Injection, USP approximated $5.6 million. As with all
products in Sagent's portfolio, Flumazenil features the Company's PreventIV
Measures^SM packaging and labeling, designed to help reduce medication errors.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in